|
⚲
|
| Keyboard |
| Lynx1 Capital Management LP
✚
|
|
|---|---|
| CRD # | 310301 |
| SEC # | 801-127585 |
| CIK # | 0001910456 |
| AUM | 626.7 M (2026-03-31) |
| Employees | 5 (80% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 929-888-7476 |
| Address | D81 Calle C Dorado, PR 00646 |
| Source | [IAPD] [EDGAR] |
| Total AUM ($M) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5. Fees and Compensation The Firm’s fees and compensation are described in its clients’ Governing Documents. All of the Firm’s clients are “qualified purchasers” (as defined in Section 2(a)(51) of the Investment Company Act of 1940, as amended). The Firm is paid management fees from the Flagship Funds quarterly in advance generally at a rate of 2.0% for Class A and 1.5% for Class B. Once paid, such management fees are non-refundable. The Firm deducts management fees from the Flagship Funds. The Firm may reduce or waive management fees with respect to any investor (including any affiliates of the Firm). The Firm does not expect that management fees will be paid with respect to shares or interests of the Flagship Funds held (directly or indirectly) by or for the benefit of the CIO, the Firm’s employees or their respective affiliates, or immediate family members of such parties. The SMA is not subject to management fees. The Lynx1 GP will be entitled receive performance-based allocations or carried interest from the Funds, as further described in Item 6 – Performance-Based Fees and Side-By-Side Management. The Firm’s compensation schedule with respect to any future client account will be contained in the Governing Documents relating to such account. The Flagship Funds will bear all of their operating expenses (collectively, the “Flagship Fund Expenses”), which expenses will include, without limitation: (i) organizational and offering expenses, (ii) expenses associated with all investments and transactions considered, evaluated and/or consummated by the Flagship Funds, as well as overall consideration and evaluation of the Flagship Funds’ portfolio, including, without limitation, those expenses incurred before the initial closing of the Flagship Funds, including, without limitation, expenses associated with sourcing, negotiating, investigating, researching, financing and structuring of investments and potential investments, whether or not consummated, including, without limitation, data and research onboarding, ingestion, aggregation, and analysis, third-party research, data, analytics, modeling, risk, structuring, pricing, execution and other third-party information systems, including, without limitation, installation and maintenance, software and service fees (including, without limitation, the expenses with respect to data, data feeds, subscriptions, expert networks, political intelligence providers and reports), (iii) the costs of research-related computer hardware and software expenses, including, without limitation, Bloomberg terminals and subscriptions and other market information systems, as well as the costs of research management systems and corporate access tracking systems, (iv) the costs of the Firm’s portfolio management system and any other software used for accounting and/or monitoring of the portfolio, including, without limitation, subscriptions relating to, among other things, trading and order management systems and services, (v) expenses associated with holding, financing, monitoring, hedging, maintaining and disposing of all investments of the Flagship Funds and all transaction and other costs associated therewith, including, without limitation, expenses associated with proxy research and voting services, (vi) travel (first-class or equivalent) and related expenses associated with investments and potential investments, (vii) professional fees associated with investments and potential investments, including, without limitation, consulting, due diligence, accounting, valuation, financial, legal and other advisory fees and expenses, (viii) transaction fees, brokerage commissions, custodial fees, clearing and settlement charges and similar fees and expenses associated with the acquisition, disposition and settling of investments and potential investments, including, without limitation, in connection with outsourced trading, (ix) expenses associated with legal and regulatory filings of the Flagship Funds in the United States, the Cayman Islands or in any other jurisdiction (including, without limitation, pursuant to Sections 13 and 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as well as the expenses associated with preparation and filing of the Firm’s Form 13F, Form 13H and Form PF, if applicable, and any other similar filing in any other U.S. or non-U.S. jurisdiction, (x) administrative, custodial, appraisal, valuation, legal, regulatory, compliance, consulting, advisory and similar fees and expenses associated with the Flagship Funds’ operations, investments and transactions, including, without limitation, fees and expenses of the Flagship Funds’ administrator and the costs of client relationship management systems, (xi) expenses incurred in connection with responding to requests or inquiries from any U.S. federal, state, local or non-U.S. governmental entity or authority, regulatory body or self-regulatory organization with respect to the Flagship Funds, (xii) broken-deal, failed transaction, break-up and similar fees, costs and expenses (if any), (xiii) costs and expenses of leverage or any other borrowings of the Flagship Funds, including, without limitation, interest charges and fees, (xiv) expenses incurred in the collection of monies owed to the Funds, (xv) auditing and accounting expenses of the Flagship Funds, including, without limitation, expenses associated with the preparation of financial statements, tax returns and Schedules K-1 and the fees and expenses of the auditor, (xvi) any entity-level taxes, fees or other governmental charges on the Flagship Funds, including, without limitation, any withholding taxes not due to the status or noncompliance of a particular investor, (xvii) costs and expenses associated with investor communications and reports and the delivery thereof to investors, (xviii) the costs of service providers or software to ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7. Types of Clients Investors in the Funds are generally institutional investors, funds of funds and high net worth individuals that qualify as “accredited investors” (as defined in Rule 501 under the Securities Act of 1933, as amended) and qualified purchasers. The minimum initial investment for the Flagship Funds is $5,000,000. The Firm has waived such minimum and, in its discretion, has the ability to do so in the future under certain circumstances. If the Firm determines to require a minimum investment for any future client accounts, it will make that determination on a case-by-case basis. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Stoke Therapeutics Inc | 155.1 | ||
| GH Research PLC | 151.3 | ||
| Cullinan Oncology Inc | 127.4 | ||
| Agios Pharmaceuticals Inc | 88.3 | ||
| Denali Therapeutics Inc | 36.1 | ||
| C4 Therapeutics Inc | 18.4 | ||
| Frequency Therapeutics Inc | 17.4 | ||
| TScan Therapeutics Inc | 8.1 | ||
| Xencor Inc | 6.5 | ||
| Precision Biosciences Inc | 5.4 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Lynx1 Opportunity Fund I LP | 2023-03-03 | ||
| HF | Lynx1 Master Fund LP | [2021-10-13] | 114.0 M | 576.8 M |
| Filed 2025-05-30 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $16,107 · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 5 | 626.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 5 | 626.7 |
| By Discretionary | ||
| Discretionary | 5 | 626.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 5 | 626.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 159.1 | |
| United States Persons | 467.6 | |
| Total | 5 | 626.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Matt Auriemma | Director | 110 | 39 | |
| Wendy Beer | Director | 19 | 11 | |
| Weston Nichols | Director | 7 | 2 | |
| Lynx1 Capital Management LP | Promoter | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001910456] | |
| 3 | [0001910456] | |
| 4 | [0001910456] | |
| SC 13D | [0001910456] | |
| SC 13G | [0001910456] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 5493003YH8Q5SHT17216 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Nichols Weston | |
| Passage Bio Inc | |
| Lynx1 Capital Management LP | |
| Korro Bio Inc | |
| TScan Therapeutics Inc | |
| Cullinan Therapeutics Inc | |
| Bionomics Limited/Fi |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
TScan Therapeutics Inc TCRX
Common Stock
|
2025-12-23 | Buy | 6,232 | $0.90 | 5,609 |
|
TScan Therapeutics Inc TCRX
Common Stock
|
2025-12-22 | Buy | 75,500 | $0.90 | 67,950 |
|
TScan Therapeutics Inc TCRX
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-12-19 | Buy | 80,069 | $0.90 | 72,062 |
|
Cullinan Therapeutics Inc CGEM
Common stock, $0.0001 par value per share
|
2025-10-28 | Buy | 165,667 | $8.40 | 1,391,603 |
|
Bionomics Limited/Fi NEUP
Common stock, $0.00001 par value per share
|
2025-10-21 | Buy | 639,110 | $5.14 | 3,285,025 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-17 | Buy | 32,217 | $7.84 | 252,581 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-16 | Buy | 150,000 | $8.86 | 1,329,000 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-15 | Buy | 51,500 | $7.94 | 408,910 |
|
Cullinan Therapeutics Inc CGEM
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-10-14 | Buy | 15,032 | $7.59 | 114,093 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-10 | Buy | 277,298 | $7.36 | 2,040,913 |
|
Cullinan Therapeutics Inc CGEM
Common Stock
|
2025-10-09 | Buy | 626,043 | $6.70 | 4,194,488 |
|
Cullinan Therapeutics Inc CGEM
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-10-08 | Buy | 556,300 | $6.46 | 3,593,698 |
|
Passage Bio Inc PASG
Common Stock
|
2025-07-24 | Buy | 66,423 | $5.71 | 379,275 |
|
Passage Bio Inc PASG
Common Stock
|
2025-07-23 | Buy | 49,302 | $5.74 | 282,993 |
|
Passage Bio Inc PASG
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-07-22 | Buy | 13,123 | $5.44 | 71,389 |
|
TScan Therapeutics Inc TCRX
Common Stock
|
2025-05-20 | Buy | 1,200,000 | $1.20 | 1,440,000 |
|
TScan Therapeutics Inc TCRX
"Common stock, $0.0001 par value per share (""Common Stock"")"
|
2025-05-19 | Buy | 1,388,794 | $1.20 | 1,666,553 |
|
Passage Bio Inc PASG
Common stock, $0.0001 par value per share
|
2024-12-27 | Buy | 373,645 | $0.65 | 242,869 |
|
TScan Therapeutics Inc TCRX
Pre-funded Warrant (right to buy) · derivative
|
2024-12-26 | Buy | 7,500,000 | $4.00 | 30,000,000 |
|
TScan Therapeutics Inc TCRX
Common Stock
|
2024-12-13 | Buy | 100,000 | $2.90 | 290,000 |
| showing 20 of 29 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
M37 Management LP
✚
|
CA | 656.4 M |
|
Altum Capital Management LLC
✚
|
NY | 647.8 M |
|
Standard General LP
✚
|
NY | 647.3 M |
|
Crow's Nest Holdings LP
✚
|
VA | 636.6 M |
|
Rose Park Advisors LLC
✚
|
MA | 629.9 M |
|
Manatuck Hill Partners LLC
✚
|
CT | 628.6 M |
|
Lago Asset Management LLC
✚
|
IL | 604.9 M |
|
Callodine Credit Management LLC
✚
|
MA | 603.0 M |
|
Endeavour Capital Advisors Inc
✚
|
CT | 602.7 M |
|
GFG Alternative Investment Advisors LLC
✚
|
CT | 599.6 M |